My aunt died of pancreatic cancer in January of 2024 after about 18 months with it. I'm sad that another few years might have saved her, but I'm happy that this will happen to a lot fewer families in the future. This is what clinical trial abundance means - fewer deaths like hers.
Although I'll say that to truly cure it and not merely extend survival, we need to really address resistance mutations and tailor treatments to a patient's specific resistance mutations. This is only feasible if we radically change our regulatory structure and the way we carry out trials.
My aunt died of pancreatic cancer in January of 2024 after about 18 months with it. I'm sad that another few years might have saved her, but I'm happy that this will happen to a lot fewer families in the future. This is what clinical trial abundance means - fewer deaths like hers.
I am sorry to hear that.
Although I'll say that to truly cure it and not merely extend survival, we need to really address resistance mutations and tailor treatments to a patient's specific resistance mutations. This is only feasible if we radically change our regulatory structure and the way we carry out trials.